Randox Health Cancer screening

Extended Cancer Risk

A genetic blood test screening 112 genes linked to inherited risk of breast, ovarian, prostate, colorectal and thyroid cancers, with a doctor-reviewed consultation.

  • Doctor reviewed
Sample
Blood
Collection
Venous draw at clinic
Results in
42 days
Biomarkers
112
Doctor reviewed
Yes
Tests for
  • AIP
  • APC
  • ATM
  • BAP1
  • BLM
  • BMPR1A
  • BRCA1
  • BRCA2
  • BRIP1
  • CDC73
  • CDH1
  • CDK4
  • +48 more

Test specifications

Provider
Randox Health
Sample type
blood
Collection method
venous draw at clinic
Turnaround time
42 days
Biomarkers tested
112
At-home test
No
Doctor reviewed
Yes
Gender focus
Both

What's tested

60 biomarkers as listed by Randox Health, of 112 in total.

  • AIP
  • APC
  • ATM
  • BAP1
  • BLM
  • BMPR1A
  • BRCA1
  • BRCA2
  • BRIP1
  • CDC73
  • CDH1
  • CDK4
  • CDKN2A
  • CEBPA
  • CHEK2
  • DDB2
  • DICER1
  • DIS3L2
  • EPCAM
  • ERCC2
  • ERCC3
  • ERCC4
  • ERCC5
  • FANCA
  • FANCB
  • FANCC
  • FANCD2
  • FANCE
  • FANCF
  • FANCG
  • FANCI
  • FANCL
  • FANCM
  • FH
  • FLCN
  • GATA2
  • GPC3
  • KIT
  • MAX
  • MEN1
  • MET
  • MLH1
  • MSH2
  • MSH6
  • MUTYH
  • NBN
  • NF1
  • NF2
  • NSD1
  • PALB2
  • PHOX2B
  • PMS2
  • PRKAR1A
  • PTCH1
  • PTEN
  • RAD51C
  • RAD51D
  • RB1
  • RECQL4
  • RET

About this test

This test screens 112 genes associated with an increased inherited risk of breast, ovarian, prostate, colorectal and thyroid cancers. A mutation across genes like these is a marker commonly used to assess hereditary cancer risk, rather than to diagnose cancer itself.

With 112 biomarkers, this has the most clinical depth of any cancer screening test we track for this provider. There are no named peer tests in our data covering this exact combination of genes, so its value-for-money score reflects that gap rather than a specific judgement on whether £887 is high or low for a panel this size.

It scores well for results and follow-up, since results are reviewed by a doctor as part of a consultation, with a genetic counsellor available beforehand. Collection convenience is lower, reflecting the venous draw and the roughly 6-week wait for results.

Who is it for?

This suits people with a strong family history across several cancer types who want the broadest genetic screen Randox offers, with expert guidance built in. Given the cost, the provider's £100 genetic counselling call beforehand, deducted from the price if you proceed, is worth using to check this is the right level of testing for your family history rather than a narrower panel like the Breast & Ovarian Cancer Risk or Bowel Cancer Risk tests.

How it works

A blood sample is taken by venous draw at a Randox clinic and analysed for mutations across 112 genes. The provider states it will make contact within 6 weeks to arrange a results consultation, reviewed by a doctor.

Pros & cons

Pros

  • Screens 112 genes across five cancer types in one test
  • Results are reviewed by a doctor as part of a consultation
  • Includes access to a genetic counsellor before testing

Cons

  • At £887, the most expensive test in this Randox catalogue
  • Results take around 6 weeks
  • No comparable named tests in our data to check the price against

Our editorial score

Compare Health Test Score Randox's broadest and most expensive test
Editorial confidence: 10.0/10

At £887, this is the most expensive test in the whole Randox catalogue we cover, screening 112 genes linked to several inherited cancer risks. It includes a doctor-reviewed consultation, though there are no directly comparable named tests in our data to check the price against.

Score breakdown

  • Clarity and documentation 9.0/10

    The listing publishes a detailed description, the full biomarker list, a stated turnaround, clear collection options, the sample type; it does not state what the report looks like.

  • Clinical depth 10.0/10

    112 biomarkers, placing it in the 100th percentile of cancer screening tests we track.

  • Collection convenience 3.0/10

    Requires a venous draw at a clinic; results in around 42 days, slower than similar tests.

  • Results and follow-up 7.0/10

    Results are reviewed by a doctor; the provider does not describe the report format.

  • Trust signals 9.0/10

    Trustpilot 4.6 from 29,705 reviews; accredited lab (UKAS ISO 15189 (Randox Clinical Laboratory Services, lab 9329)); CQC registered.

  • Value for money 6.0/10

    £887.00; no comparable tests to benchmark against yet.

Calculated 13 September 2026 from the facts we hold about this test and provider, using our published scoring formula. Scores are not hand-edited.

More in Cancer screening

View all →
Selph

qFIT Bowel Cancer Screening Test

Priced close to the FIT test group median

A stool test using the qFIT method to measure blood in a stool sample, giving a numerical result rather than a simple positive or negative. Suited to adults wanting to check a common early indicator of possible bowel cancer risk.

  • At-home test
8.1 / 10
£59.00
Full review →